The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors.

Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck ...

After living with lymphoma for 15 and a half years, my doctor has suggested reducing the dose of my medication and possibly ...

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was ...

Dr. Sheri Yolanda Prentiss discusses lymphedema as a result of cancer treatment and shares resources that exist for patients ...

Because the five-year relative survival rate for people with esophageal cancer is approximately 22%, this makes early ...